Pharmaceuticals company buys global rights to new technology from Japan’s Daiichi Sankyo
Drugmaker AstraZeneca could pay up to $6bn (£4.7bn) for the global rights to a new Japanese cancer treatment.
The Anglo-Swedish pharmaceutical company said it would pay $1bn (£800m) up front to its partner Daiichi Sankyo.
Related: Covid-19 is Big Pharma’s chance to impress. But who’ll do best?
